NO3092234T3 - - Google Patents

Info

Publication number
NO3092234T3
NO3092234T3 NO14819206A NO14819206A NO3092234T3 NO 3092234 T3 NO3092234 T3 NO 3092234T3 NO 14819206 A NO14819206 A NO 14819206A NO 14819206 A NO14819206 A NO 14819206A NO 3092234 T3 NO3092234 T3 NO 3092234T3
Authority
NO
Norway
Application number
NO14819206A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50729472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO3092234(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO3092234T3 publication Critical patent/NO3092234T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
NO14819206A 2013-05-03 2014-12-03 NO3092234T3 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/887,014 US9549909B2 (en) 2013-05-03 2013-05-03 Method for the treatment of dravet syndrome

Publications (1)

Publication Number Publication Date
NO3092234T3 true NO3092234T3 (no) 2018-07-14

Family

ID=50729472

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14819206A NO3092234T3 (no) 2013-05-03 2014-12-03

Country Status (17)

Country Link
US (13) US9549909B2 (no)
EP (2) EP2991637B1 (no)
JP (3) JP6441313B2 (no)
AU (4) AU2014261329B2 (no)
BR (1) BR112015027282A8 (no)
CA (1) CA2909335C (no)
CY (1) CY1124298T1 (no)
DK (2) DK2991637T3 (no)
ES (2) ES2666657T3 (no)
HR (1) HRP20210819T1 (no)
HU (1) HUE054577T2 (no)
LT (1) LT3329909T (no)
NO (1) NO3092234T3 (no)
PL (2) PL3329909T3 (no)
PT (2) PT2991637T (no)
SI (1) SI3329909T1 (no)
WO (1) WO2014177676A1 (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
US10452815B2 (en) 2014-09-29 2019-10-22 Zogenix International Limited Control system for control of distribution of medication
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
LT3261640T (lt) * 2015-02-25 2022-07-11 The Regents Of The University Of California 5ht agonistai epilepsijos sutrikimų gydymui
JP6668045B2 (ja) * 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
BR112018002046A2 (pt) * 2015-08-24 2018-09-18 Zogenix International Ltd métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
AU2016334804B2 (en) 2015-10-09 2022-03-31 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
AU2016379346B2 (en) 2015-12-22 2021-02-18 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
KR20180095674A (ko) 2015-12-22 2018-08-27 조게닉스 인터내셔널 리미티드 대사 저항성 펜플루라민 유사체 및 그 사용 방법
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
CA3032996A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US20180092864A1 (en) * 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
CA3043626A1 (en) * 2016-11-22 2018-05-31 Ovid Therapeutics Inc. Methods of treating attention deficit/hyperactivity disorder with gaboxadol
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
CA3059775A1 (en) * 2017-04-13 2018-10-18 Ovid Therapeutics Inc. Methods of treating developmental encephalopathies
JP2020519594A (ja) * 2017-05-09 2020-07-02 ゾゲニクス インターナショナル リミテッド フェンフルラミンを用いるドゥーゼ症候群の治療方法
KR102643936B1 (ko) 2017-08-25 2024-03-05 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US20190091174A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Method of reducing seizure type experienced by a dravet patient
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019067413A1 (en) * 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
JP2021523227A (ja) 2018-05-04 2021-09-02 ストーク セラピューティクス，インク． コレステリルエステル蓄積症の処置のための方法及び組成物
JP2021526507A (ja) * 2018-05-11 2021-10-07 ゾゲニクス インターナショナル リミテッド 発作により誘発される突然死を処置するための組成物および方法
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
WO2020014075A1 (en) * 2018-07-10 2020-01-16 Zogenix International Limited Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension
SG11202100682YA (en) * 2018-07-27 2021-02-25 Xenon Pharmaceuticals Inc Method for treating epilepsy
EP3930841A4 (en) * 2019-02-25 2022-11-30 Zogenix International Limited FORMULATION TO IMPROVE SEIZURE CONTROL
CN111944835B (zh) * 2019-05-14 2022-03-29 南通大学 一种突变型gabrg2转基因斑马鱼癫痫模型的构建方法及应用
EP4021454A1 (en) * 2019-08-30 2022-07-06 Research Institute at Nationwide Children's Hospital Copper-atsm for treating neurodegenerative disorders associated with mitochondrial dysfunction
JP2022548892A (ja) * 2019-09-17 2022-11-22 ゾゲニクス インターナショナル リミテッド てんかん患者をフェンフルラミンで治療する方法
US20210299064A1 (en) 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
WO2021231107A1 (en) 2020-05-11 2021-11-18 Stoke Therapeutics, Inc. Opa1 antisense oligomers for treatment of conditions and diseases
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL270984A (no) 1960-11-05
US3117160A (en) 1961-07-27 1964-01-07 Pfizer & Co C Aralkylamines
US3198834A (en) 1964-07-27 1965-08-03 Snc Science Union Et Compagnie Optical isomers of trifluoromethylated phenethylamines
GB1254332A (en) 1969-02-27 1971-11-17 Science Union & Cie Amino acids and their derivatives and processes for preparing them
DE2143204C3 (de) 1971-08-28 1979-09-27 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis
DE2150399A1 (de) 1971-10-09 1973-04-12 Hoechst Ag Neue oxime
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
US4309445A (en) 1980-06-16 1982-01-05 Massachusetts Institute Of Technology d-Fenfluramine for modifying feeding behavior
US4452815A (en) 1980-06-16 1984-06-05 Massachusetts Institute Of Technology Method of utilizing d,l-fenfluramine for modifying feeding behavior
DE3717434C1 (de) 1987-05-23 1988-09-15 Degussa Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril
KR890003368A (ko) 1987-08-06 1989-04-14 원본미기재 특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법
US4857553A (en) 1987-08-06 1989-08-15 A. H. Robins Company, Incorporated Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
HU204497B (en) 1989-10-09 1992-01-28 Chinoin Gyogyszer Es Vegyeszet Process for producing phenfluramine
IT1238686B (it) 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
FR2663539B1 (fr) 1990-06-22 1994-10-07 Adir Utilisation de la d-fenfluramine pour l'obtention de medicaments destines au traitement des deficiences immunitaires chez le sujet age.
FR2684552B1 (fr) 1991-12-06 1995-04-28 Adir Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
FR2685204B1 (fr) 1991-12-19 1995-06-16 Palmer Research Compositions pharmaceutiques pour l'administration transcutanee de la fenfluramine.
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
WO1995004713A1 (en) 1993-08-06 1995-02-16 The Upjohn Company 2-aminoindans as selective dopamine d3 ligands
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5412102A (en) 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
WO1995033455A1 (en) 1994-06-03 1995-12-14 Elmaleh David R Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof
IT1298349B1 (it) 1996-05-29 2000-01-05 Alfa Chem Ital Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina
IT1292885B1 (it) 1997-04-28 1999-02-11 Alfa Chem Ital Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina.
EP0920864A1 (en) 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
US20020098175A1 (en) 1998-06-16 2002-07-25 Zohoungbogbo Mathias C. Dietetic food composition and dietetic method using such composition
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
WO2000038672A2 (en) 1998-12-23 2000-07-06 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7124031B1 (en) 2000-05-11 2006-10-17 Medco Health Solutions, Inc. System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
US20020032581A1 (en) 2000-07-17 2002-03-14 Reitberg Donald P. Single-patient drug trials used with accumulated database: risk of habituation
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
WO2003000047A2 (en) 2001-06-22 2003-01-03 Universite Catholique De Louvaine Hydrogel beads or capsules as artificial media for insects oviposition and rearing of endoparasitoids
JP2004538309A (ja) 2001-07-31 2004-12-24 ワイエス 不快な味覚をマスキングするためのスクラロース調合物
AUPR732601A0 (en) 2001-08-28 2001-09-20 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of amines such as ephedrine and inter mediates
BR0212985A (pt) 2001-09-24 2005-08-30 Imp College Innovations Ltd Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso
RU2317104C2 (ru) 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
US6599901B1 (en) 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
JP2005531520A (ja) 2002-03-28 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド 置換２，３−ジフェニルピリジン類
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
WO2005004865A1 (en) 2003-07-08 2005-01-20 Georg-August-Universität Göttingen Use of 5-ht4(a)-serotonin receptor agonists
GB0410266D0 (en) 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
US20050260610A1 (en) 2004-05-20 2005-11-24 Kurtz Richard E Method for diagnosing and prescribing a regimen of therapy for human health risk
US9820658B2 (en) 2006-06-30 2017-11-21 Bao Q. Tran Systems and methods for providing interoperability among healthcare devices
US20060079582A1 (en) 2004-09-23 2006-04-13 Jeffrey Jonas Memantine for the treatment of childhood behavioral disorders
CN100567252C (zh) 2004-10-11 2009-12-09 俞锋 盐酸芬氟拉明原料药和片剂及其制备方法
US20090216132A1 (en) 2005-03-21 2009-08-27 Tuvi Orbach System for Continuous Blood Pressure Monitoring
CN101257889A (zh) 2005-05-25 2008-09-03 詹森药业有限公司 托吡酯的儿科制剂
WO2006133199A2 (en) 2005-06-06 2006-12-14 University Of South Florida Treatment with sigma receptor agonists post-stroke
JP2008546376A (ja) 2005-06-16 2008-12-25 バイオノミックス リミテッド Ｓｃｎ１ａ遺伝子における変異を検出することによっててんかんを診断および処置するための方法
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
US9125900B2 (en) 2005-09-14 2015-09-08 University Of The Witwatersrand, Johannesburg Pharmaceutical composition
CA2622967A1 (en) 2005-09-19 2007-03-29 Biolert Ltd. A system and method for detecting an epileptic event
EP3223182A1 (en) 2005-11-29 2017-09-27 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007079181A2 (en) 2005-12-28 2007-07-12 Neurovista Corporation Methods and systems for recommending an action to a patient for managing epilepsy and other neurological disorders
KR20080091473A (ko) 2006-02-06 2008-10-13 노파르티스 아게 유기 화합물들의 조합물
DE102006030113B4 (de) 2006-06-28 2009-02-12 Chemische Fabrik Budenheim Kg Graphitfreier Hochtemperatur-Schmierstoff
US20110184747A1 (en) 2006-08-09 2011-07-28 Carmen Bozic Method for distribution of a drug
CA2660431C (en) 2006-08-31 2015-03-17 The Governors Of The University Of Alberta Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators
WO2008095095A2 (en) 2007-01-31 2008-08-07 Quintiles Transnational Corp. Methods and systems for allocating representatives to sites in clinical trials
PT2139467T (pt) 2007-02-08 2016-12-16 Biogen Ma Inc Neuroproteção em doenças desmielinizantes
JP2010520162A (ja) 2007-02-28 2010-06-10 スミスクライン ビーチャム コーポレーション ステアロイル−ＣｏＡデサチュラーゼ阻害剤であるチアジアゾール誘導体
WO2009082039A1 (en) 2007-12-26 2009-07-02 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
WO2010015029A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
WO2010020585A1 (en) 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
RU2674150C1 (ru) 2008-09-05 2018-12-05 Грюненталь Гмбх Фармацевтическая комбинация
US8386274B1 (en) 2008-09-17 2013-02-26 Mckesson Financial Holdings Limited Systems and methods for a prescription safety network utilizing eligibility verification transactions
EP2349207B1 (en) 2008-10-09 2015-05-13 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Liquid pharmaceutical formulation containing paracetamol
EP2355818A4 (en) 2008-10-10 2012-04-11 Us Of America As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Inst Of Res METHODS AND COMPOSITIONS FOR TREATING A CONDITION OF EPILEPTIC DISEASE AND EPILEPSY CRISES CAUSING EPILEPTIC DISEASE CONDITION
TWI503101B (zh) 2008-12-15 2015-10-11 Proteus Digital Health Inc 與身體有關的接收器及其方法
US20120065999A1 (en) 2009-03-09 2012-03-15 Celgene Corporation Device for Delivering a Drug to a Patient While Restricting Access to the Drug by Patients for Whom the Drug May Be Contraindicated and Methods for Use Thereof
EP2419400A1 (en) 2009-04-15 2012-02-22 Research Triangle Institute Monoamine reuptake inhibitors
WO2010124137A1 (en) 2009-04-22 2010-10-28 Millennium Pharmacy Systems, Inc. Pharmacy management and administration with bedside real-time medical event data collection
US9453027B2 (en) 2009-07-27 2016-09-27 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
US20110212171A1 (en) 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
CA2792507C (en) 2010-03-09 2018-05-22 Perceptimed, Inc. Medication verification and dispensing
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
JP2011221623A (ja) 2010-04-06 2011-11-04 Kakimori Suri 在宅診療支援システム及び方法
CA2800220C (en) 2010-05-21 2019-04-30 Research Triangle Institute Phenylmorpholines and analogues thereof
EP2399513B1 (en) 2010-06-23 2017-01-04 Qatar University Qstp-B System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms
EP2598159A4 (en) 2010-07-30 2014-01-08 Merck Sharp & Dohme INHIBITION OF CYP3A METABOLISM OF THE MEDICINAL PRODUCT
SG188362A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Modified-release dosage forms of 5-ht2c agonists useful for weight management
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
AU2011322147A1 (en) 2010-10-26 2013-04-18 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose
RU103209U1 (ru) 2010-10-29 2011-03-27 Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" Клиническая информационная система
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
US10183008B2 (en) 2011-02-09 2019-01-22 University Of South Carolina Treatment of prolonged status epilepticus
JP5693325B2 (ja) 2011-03-29 2015-04-01 小林クリエイト株式会社 健診結果出力システム及び健診結果出力プログラム
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US10092750B2 (en) 2011-11-11 2018-10-09 Neuroenabling Technologies, Inc. Transcutaneous neuromodulation system and methods of using same
US20140348966A1 (en) 2011-12-22 2014-11-27 Onesmo B. Balemba Garcinia buchananii baker compounds, compositions and related methods
CA2862816A1 (en) 2012-01-27 2013-08-01 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
US9346798B2 (en) 2012-02-13 2016-05-24 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US20130218586A1 (en) 2012-02-21 2013-08-22 Frederic J. Huser Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status
JP6075973B2 (ja) 2012-06-04 2017-02-08 富士通株式会社 健康状態判定装置およびその作動方法
KR20150082633A (ko) 2012-11-15 2015-07-15 갈레온 파마슈티칼스, 인코포레이티드 경구적으로 생체이용가능한 신규 호흡 조절 제어 화합물 및 그의 사용 방법
WO2014106825A2 (en) 2013-01-06 2014-07-10 Jonathan Rabinowitz Methods and devices for identifying improper medical reporting
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
ES2797374T3 (es) 2013-07-25 2020-12-02 Neuren Pharmaceuticals Ltd Compuestos bicíclicos neuroprotectores y métodos para su uso en el tratamiento de trastornos del espectro autista y trastornos del neurodesarrollo
RS61038B1 (sr) 2013-08-19 2020-12-31 Univ California Jedinjenja i metodi za lečenje epileptičnog poremećaja
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US20150141415A1 (en) 2013-11-20 2015-05-21 Omonike Arike Olaleye Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases
CN103886415A (zh) 2014-03-25 2014-06-25 北京蝶禾谊安信息技术有限公司 药品管理方法和装置
WO2015163098A1 (ja) 2014-04-22 2015-10-29 国立大学法人東北大学 肺高血圧症の検査方法
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
WO2016003966A1 (en) 2014-06-30 2016-01-07 University Of Cincinnati Non-invasive detection of spreading depolarization using scalp electroencephalography
US10452815B2 (en) 2014-09-29 2019-10-22 Zogenix International Limited Control system for control of distribution of medication
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US20160228454A1 (en) 2015-02-06 2016-08-11 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and methods of use in treating status epilepticus and other seizure disorders
LT3261640T (lt) 2015-02-25 2022-07-11 The Regents Of The University Of California 5ht agonistai epilepsijos sutrikimų gydymui
US10292996B2 (en) 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
CN104800168A (zh) 2015-04-08 2015-07-29 石家庄四药有限公司 司替戊醇干混悬剂及其制备方法
JP6668045B2 (ja) 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
MX2020000269A (es) 2015-06-17 2022-01-03 Univ Columbia Terapia con desoxinucleósidos para enfermedades generadas por grupos de nucleótidos desequilibrados, inclusive síndromes de agotamiento del adn mitocondrial.
CA2989885A1 (en) 2015-06-30 2017-01-05 Neurad Ltd. Novel breathing control modulating compounds, and methods of making and using same
ES2925951T3 (es) 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
BR112018002046A2 (pt) 2015-08-24 2018-09-18 Zogenix International Ltd métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
US20220193082A1 (en) 2015-09-14 2022-06-23 Zogenix International Limited Combination treatment of specific forms of epilepsy
US20170071949A1 (en) 2015-09-14 2017-03-16 Zogenix International Limited Combination treatment of specific forms of epilepsy
EP3170807B1 (en) 2015-11-23 2019-12-11 Frau Pharma S.r.l. New method for synthesis of fenfluramine
AU2016379346B2 (en) 2015-12-22 2021-02-18 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
KR20180095674A (ko) 2015-12-22 2018-08-27 조게닉스 인터내셔널 리미티드 대사 저항성 펜플루라민 유사체 및 그 사용 방법
WO2017122701A1 (ja) 2016-01-14 2017-07-20 旭硝子株式会社 フッ素樹脂含有溶液、フッ素樹脂含有溶液の製造方法、塗料組成物および塗装物品
ES2882175T3 (es) 2016-03-28 2021-12-01 Takeda Pharmaceuticals Co Compuestos para su uso en el tratamiento de la hipertensión pulmonar
US20190083425A1 (en) 2016-08-24 2019-03-21 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
CA3032996A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US20180092864A1 (en) 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
JP2020506240A (ja) 2017-02-08 2020-02-27 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 発作性障害およびプラダー・ウィリー症候群の治療方法
JP2020519594A (ja) 2017-05-09 2020-07-02 ゾゲニクス インターナショナル リミテッド フェンフルラミンを用いるドゥーゼ症候群の治療方法
US20190091174A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Method of reducing seizure type experienced by a dravet patient
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US20190247333A1 (en) 2017-09-26 2019-08-15 Zogenix International Limited Method of reduction in convulsive seizure frequency
WO2019067413A1 (en) 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
MX2020010994A (es) 2018-04-18 2021-01-08 Univ Columbia Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial.
JP2021526507A (ja) 2018-05-11 2021-10-07 ゾゲニクス インターナショナル リミテッド 発作により誘発される突然死を処置するための組成物および方法
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
WO2020014075A1 (en) 2018-07-10 2020-01-16 Zogenix International Limited Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension
SG11202100682YA (en) 2018-07-27 2021-02-25 Xenon Pharmaceuticals Inc Method for treating epilepsy
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
US20210401776A1 (en) 2018-11-30 2021-12-30 Zogenix International Limited Method of treating refractory epilepsy syndromes using fenfluramine enantiomers
EP3930841A4 (en) 2019-02-25 2022-11-30 Zogenix International Limited FORMULATION TO IMPROVE SEIZURE CONTROL
US20210299064A1 (en) 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20220096514A1 (en) 2020-09-29 2022-03-31 Zogenix International Limited Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine
JP2024533015A (ja) 2021-09-01 2024-09-12 ゾゲニクス インターナショナル リミテッド 脱髄性の疾患および病状の処置のためのフェンフルラミン
US20230165810A1 (en) 2021-12-01 2023-06-01 Zogenix International Limited Fenfluramine for treatment of conditions associated with spreading depolarization

Also Published As

Publication number Publication date
JP2020063309A (ja) 2020-04-23
HUE054577T2 (hu) 2021-09-28
EP3329909A1 (en) 2018-06-06
US20170151213A1 (en) 2017-06-01
DK2991637T3 (en) 2018-05-07
US12097206B2 (en) 2024-09-24
LT3329909T (lt) 2021-07-12
US20210121479A1 (en) 2021-04-29
AU2019203448B2 (en) 2020-08-06
AU2020267264A1 (en) 2020-12-17
PL3329909T3 (pl) 2021-10-11
JP6655156B2 (ja) 2020-02-26
US20200030341A1 (en) 2020-01-30
US20170151214A1 (en) 2017-06-01
JP6441313B2 (ja) 2018-12-19
JP6966584B2 (ja) 2021-11-17
DK3329909T3 (da) 2021-04-19
US20220160727A1 (en) 2022-05-26
US20140329908A1 (en) 2014-11-06
EP3329909B1 (en) 2021-03-17
US9603815B2 (en) 2017-03-28
US9603814B2 (en) 2017-03-28
ES2666657T3 (es) 2018-05-07
CY1124298T1 (el) 2022-07-22
US20170151257A1 (en) 2017-06-01
SI3329909T1 (sl) 2021-08-31
CA2909335A1 (en) 2014-11-06
US10478441B2 (en) 2019-11-19
US20140343162A1 (en) 2014-11-20
US9549909B2 (en) 2017-01-24
CA2909335C (en) 2021-05-18
US20160136114A1 (en) 2016-05-19
PT3329909T (pt) 2021-05-14
JP2016518387A (ja) 2016-06-23
US20170151259A1 (en) 2017-06-01
AU2014261329A1 (en) 2015-11-05
ES2863929T3 (es) 2021-10-13
BR112015027282A2 (pt) 2017-07-25
PT2991637T (pt) 2018-04-24
WO2014177676A1 (en) 2014-11-06
AU2019203832A1 (en) 2019-06-20
AU2019203448A1 (en) 2019-06-06
HRP20210819T1 (hr) 2021-08-20
US10478442B2 (en) 2019-11-19
US9610260B2 (en) 2017-04-04
JP2019048862A (ja) 2019-03-28
AU2019203832B2 (en) 2020-10-15
US20140343044A1 (en) 2014-11-20
PL2991637T3 (pl) 2018-07-31
EP2991637B1 (en) 2018-03-07
AU2014261329B2 (en) 2019-02-21
BR112015027282A8 (pt) 2019-12-24
EP2991637A1 (en) 2016-03-09
US20140343161A1 (en) 2014-11-20
US20170151194A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
AP2016009275A0 (no)
NO3092234T3 (no)
BR112015007533A2 (no)
BR102016010778A2 (no)
BR112014017733A2 (no)
BR112014017739A2 (no)
BR112014018502A2 (no)
BR112014019326A2 (no)
BR112014018516A2 (no)
BR112014020341A2 (no)
BR112014018480A2 (no)
BR112014017855A2 (no)
BR112014017765A2 (no)
BR112014017669A2 (no)
BR112014021878A2 (no)
BR112014018468A2 (no)
BR112014017901A2 (no)
BR112014018207A2 (no)
BR112014019204A2 (no)
BR112014017722A2 (no)
BR112015015948A2 (no)
BR112014018578A2 (no)
BR112014018483A2 (no)
BR112014017794A2 (no)
BR112014017653A2 (no)